|
Market Closed -
Euronext Paris
11:55:00 2026-08-12 EDT
|
5-day change | 1st Jan Change | ||
| 0.3890 EUR | +1.04% |
|
+2.37% | +30.54% |
| 08-10 | Nicox Sa and Ocumension Therapeutics Submit Ncx 470 New Drug Application in China | CI |
| 08-10 | Nicox Partner Files China Drug Application for NCX 470 Eye Drop | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 39.15M | - | - | - | ||
| 322B | |||||
| 70.24B | |||||
| 11.65B | |||||
| 8.42B | |||||
| 5.02B |
- Stock Market
- Stocks
- ALCOX Stock
- Charts Nicox SA
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
